Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors
作者:Le Wang、John K. Pratt、Todd Soltwedel、George S. Sheppard、Steven D. Fidanze、Dachun Liu、Lisa A. Hasvold、Robert A. Mantei、James H. Holms、William J. McClellan、Michael D. Wendt、Carol Wada、Robin Frey、T. Matthew Hansen、Robert Hubbard、Chang H. Park、Leiming Li、Terrance J. Magoc、Daniel H. Albert、Xiaoyu Lin、Scott E. Warder、Peter Kovar、Xiaoli Huang、Denise Wilcox、Rongqi Wang、Ganesh Rajaraman、Andrew M. Petros、Charles W. Hutchins、Sanjay C. Panchal、Chaohong Sun、Steven W. Elmore、Yu Shen、Warren M. Kati、Keith F. McDaniel
DOI:10.1021/acs.jmedchem.7b00017
日期:2017.5.11
Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen for binders to the bromodomains of BRD4 identified a phenylpyridazinone fragment with a weak binding affinity (1, Ki = 160 μM). SAR investigation of fragment 1, aided by X-ray structure-based design
含溴结构域的蛋白质的BET家族成员已被鉴定为在多种癌细胞系中阻断增殖的潜在靶标。针对BRD4溴结构域的结合剂的二维NMR片段筛选确定了结合亲和力较弱(1,Ki = 160μM)的苯基哒嗪酮片段。片段1的SAR研究,借助基于X射线结构的设计,使得能够合成有效的吡啶酮和大环吡啶酮抑制剂,这些抑制剂在生化和基于细胞的测定中均显示出单位数纳摩尔的效力。这些系列中的高级类似物在啮齿动物PK研究中表现出较高的口服暴露量,并在小鼠侧翼异种移植模型中显示出显着的肿瘤生长抑制功效。